Head to Head Review: Akebia Therapeutics (NASDAQ:AKBA) versus Ainos (NASDAQ:AIMD)

Ainos (NASDAQ:AIMD) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Ainos and Akebia Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1	0	0	0	1.00
Akebia Therapeutics	2	0	4	1	2.57

Akebia Therapeutics has a consensus target price of $5.40, suggesting a potential upside of 280.28%. Given Akebia Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Ainos.

Insider and Institutional Ownership

33.9% of Akebia Therapeutics shares are owned by institutional investors. 9.8% of Ainos shares are owned by company insiders. Comparatively, 3.0% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Ainos and Akebia Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	-119.36%	-58.78%
Akebia Therapeutics	-2.26%	-16.70%	-1.53%

Valuation and Earnings

This table compares Ainos and Akebia Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$20,000.00	348.73	-$14.86 million	($3.98)	-0.36
Akebia Therapeutics	$236.20 million	1.61	-$5.34 million	($0.02)	-71.00

Akebia Therapeutics has higher revenue and earnings than Ainos. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ainos has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.

Summary

Akebia Therapeutics beats Ainos on 10 of the 15 factors compared between the two stocks.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.